(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(-1.22%) $77.99
(5.65%) $2.15
(0.02%) $2 310.10
(-0.16%) $26.79
(0.37%) $966.20
(-0.35%) $0.929
(-1.07%) $10.87
(-0.11%) $0.797
(0.35%) $91.45
Quarter results tomorrow
(bmo 2024-05-06)
Expected move: +/- 8.74%
10.98% $ 1.920
Live Chart Being Loaded With Signals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies...
Stats | |
---|---|
Dzisiejszy wolumen | 360 645 |
Średni wolumen | 208 873 |
Kapitalizacja rynkowa | 94.15M |
EPS | $0 ( 2024-03-26 ) |
Następna data zysków | ( $-0.120 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.43 |
ATR14 | $0.0280 (1.47%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-28 | Arcara Jeffrey | Buy | 400 000 | Stock Option (Right to Buy) |
2024-02-02 | Arcara Jeffrey | Buy | 0 | |
2023-12-06 | Miller Richard A Md | Buy | 500 000 | Stock Option (Right to Buy) |
2023-12-06 | Lea Leiv | Buy | 200 000 | Stock Option (Right to Buy) |
2023-12-06 | Jones William Benton | Buy | 200 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 97 transactions |
Buy: 8 310 910 | Sell: 8 757 350 |
Wolumen Korelacja
Corvus Pharmaceuticals Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
GNLN | 0.95 |
VTGN | 0.947 |
AQST | 0.943 |
LIXT | 0.936 |
OMCL | 0.924 |
FLGC | 0.921 |
BBLG | 0.92 |
NNOX | 0.917 |
NERV | 0.914 |
APTO | 0.914 |
10 Najbardziej negatywne korelacje | |
---|---|
PRAA | -0.957 |
PEBK | -0.95 |
IEP | -0.931 |
LEXX | -0.928 |
FOXF | -0.927 |
CRWS | -0.916 |
PROV | -0.911 |
FARO | -0.911 |
VORB | -0.91 |
PINC | -0.909 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Corvus Pharmaceuticals Korelacja - Waluta/Towar
Corvus Pharmaceuticals Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-151 000 (0.00 %) |
EPS: | $-0.560 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-151 000 (0.00 %) |
EPS: | $-0.560 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-367 000 (0.00 %) |
EPS: | $-1.080 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.030 |
Financial Reports:
No articles found.
Corvus Pharmaceuticals
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej